|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||79.91 - 79.91|
|52-week range||68.34 - 89.71|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||17.44|
|Forward dividend & yield||1.64 (2.05%)|
|Ex-dividend date||24 May 2021|
|1y target est||N/A|
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Half Year Results30.07.2021 / 07:03 The issuer is solely responsible for the content of this announcement. As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses Patient excess mortality rates significantly reduced Negative exchange rate effects continue Earnings development impacted by phasing and strong prior-year base, as indicated Financial targets for FY 2021 confirmed FME25 progra
Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.